| Bioactivity | CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC50 of 6.8 nM in calcium flux assay[1]. | ||||||||||||
| Invitro | CCR1 antagonist 9 (Compound 19e) blocks the CCR1 chemotaxis of THP-1 cells with an IC50 of 28 nM. CCR1 antagonist 9 also blocks hERG with an IC50 of 30 μM[1]. | ||||||||||||
| Name | CCR1 antagonist 9 | ||||||||||||
| CAS | 1220026-26-5 | ||||||||||||
| Formula | C20H16FN5O3S | ||||||||||||
| Molar Mass | 425.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448. |